FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / term-sheet-penterra-meridian.docx
term-sheet-penterra-meridian.docx · 1018-00006

Parties

Penterra Pharmaceuticals Corp
Hong Kong SA
Sublicense Inc
Alkerra Manufacturing Inc
Meridian Korea Inc
Meridian Bio Australia Pty Ltd

Dates

August 4, 2023
March 15, 2022
August 12, 2037
July 22, 2022
November 3, 2038

Amounts

$18,000,000
$32,000,000
$6,000,000
$8,000,000
$10,000,000
$25,000,000
$4,000,000
$3,000,000
$45,000,000
$15,000,000

Obligations

Indication: The initial therapeutic indication for development and commercialization under the Definitive Agreement shall be moderate-to-severe atopic dermatitis in adult patients
The license shall include the right to grant sublicenses within the Territory, subject to the conditions and limitations described in Section 14 below
Upon satisfaction of all Closing conditions, the Escrow Agent shall release the escrowed funds to Penterra in accordance with the terms of the Escrow Agreement described in Section 26 below
If the Closing does not occur by the outside date to be agreed in the Definitive Agreement, the escrowed funds shall be returned to Meridian, less any Escrow Agent fees attributable to Meridian's share
For the avoidance of doubt, if the same milestone event is achieved by more than one Licensed Product or in more than one indication, no additional development milestone payment shall be due with respect to the subsequent achievement of such milestone event
Meridian shall promptly notify Penterra of the achievement of each milestone event, and in no event later than fifteen (15) business days following such achievement